By now most rheumatologists are aware that checkpoint inhibitors are capable of unleashing a wide array of autoimmune and autoinflammatory adverse events within virtually every organ system. These complications have posed new challenges to all practitioners.
Individuals with clinically unapparent HBV and concomitant immune-mediated inflammatory diseases (IMIDs) (e.g., rheumatoid arthritis, psoriasis, inflammatory bowel disease and others) are particularly vulnerable to HBV reactivation when immunosuppressed.
A dynamic interaction between the peripheral immune system and the CNS is fueling enthusiasm for immunotherapeutic approaches to glioblastoma. Here’s a look at a range of trials of various strategies.
Immunological therapy is changing how oncologists treat cancers—not just hematologic malignancies, but also solid tumors.
Cleveland Clinic is a non-profit academic medical center. Advertising on our site helps support our mission. We do not endorse non-Cleveland Clinic products or services Policy
Patients with metastatic or locally advanced urothelial cancer treated with chemotherapy, or those who are not candidates for cisplatin-based chemotherapy, may have hope in newer immunotherapeutic agent pembrolizumab.
A 13-year-old’s super-refractory status epilepticus lands her in the pediatric ICU. Meticulous review of her history ultimately reveals the uncommon source of an immune reaction underlying her chronic epilepsy.
Two studies show that a new combination immunotherapy regimen can produce remission in some patients and improve survival in metastatic melanoma and kidney cancer.
A retrospective study investigating the impact of BRAF mutation on overall survival and treatment response in metastatic brain melanoma patients shows that stereotactic radiosurgery improves survival in BRAF-positive patients.
Early data from renal cancer dual drug trial reinforces cancer field’s optimism for immunotherapy approaches.